Uncategorized
Monthly ranibizumab beneficial in treatment of recalcitrant neovascular AMD
Patients with recalcitrant neovascular age-related macular degeneration achieved visual and anatomic gains out to 1 year after receiving monthly doses of 2 mg ranibizumab, according to a recent trial.The phase 1-2 super-dose anti-VEGF trial, or SAVE, included 88 patients with recalcitrant neovascular AMD who were categorized into two groups after three initial monthly injections of 2 mg Lucentis (ranibizumab, Genentech): cohort A received 2 mg ranibizumab as need every 4 weeks, and cohort B received the same treatment as needed every 6 weeks.